Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Low Grade Glioma of Brain With Neurofibromatosis Type 1”

4 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 4 of 4 results

Post-approval studies (Phase 4)Active Not RecruitingNCT03975829
What this trial is testing

Pediatric Long-Term Follow-up and Rollover Study

Who this might be right for
Diffuse AstrocytomaAnaplastic AstrocytomaAstrocytoma+20 more
Novartis Pharmaceuticals 163
Testing effectiveness (Phase 2)Active Not RecruitingNCT03363217
What this trial is testing

Trametinib for Pediatric Neuro-oncology Patients With Refractory Tumor and Activation of the MAPK/ERK Pathway.

Who this might be right for
Low-grade GliomaPlexiform NeurofibromaCentral Nervous System Glioma
St. Justine's Hospital 114
Early research (Phase 1)Study completedNCT00352495
What this trial is testing

Vinblastine and Carboplatin in Treating Young Patients With Newly Diagnosed or Recurrent Low-Grade Glioma

Who this might be right for
Brain and Central Nervous System TumorsNeurofibromatosis Type 1
Children's Oncology Group 26
Testing effectiveness (Phase 2)Active Not RecruitingNCT04201457
What this trial is testing

A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration

Who this might be right for
Low Grade Glioma (LGG) of Brain With BRAF AberrationHigh Grade Glioma (HGG) of the Brain With BRAF AberrationLow Grade Glioma of Brain With Neurofibromatosis Type 1
Pediatric Brain Tumor Consortium 57